Respiratory virus infections, such as influenza A, cause significant morbidity in hematopoietic stem cell transplantation (HSCT) recipients. The clinical characteristics and impact of infection with the novel H1N1 virus in this patient population is not yet well defined, however. HSCTrecipients diagnosed with proven or probable H1N1 during the 2009 pandemic were identified and charts were retrospectively reviewed with analysis of clinical descriptions, risk factors, diagnosis, treatments, and outcomes. Twenty-seven patients from two medical centers were identified. Fever and cough were the most common presenting symptoms. The incidence of influenza lower respiratory tract infection (LRTI) was 52% (14/27). Compared with patients with LRTI, those with influenza upper respiratory tract infection (URTI) were more likely to have a classic influenza-like syndrome. Compared to patients with URTI, those with LRTI were started on antiviral therapy significantly later after symptom onset (3.0 days vs 6.58 days after onset of symptoms; P 5 .03; 95% confidence interval [CI], 0.29-6.8). Overall influenza-related 30-day mortality was 22% (6/27), and that in patients with LRTI was 43% (6/14). Chronic steroid use ($20 mg/day of prednisone equivalent) at the time of presentation was associated with LRTI (P 5 .006) and mortality (P 5 .003) on univariate analysis. Five cases were hospitalacquired. In this first season of the novel H1N1 pandemic, infection in HSCT often presented as an atypical severe illness with a high incidence of LRTI and high mortality.
INTRODUCTION
Influenza A is a single-stranded RNA virus of the orthomyxovirus family. Novel H1N1 influenza A is a reassortment of classic swine H1N1, avian Eurasian swine H1N1, and North American human H2N2 [1, 2] . Subsequent to the onset of clinical disease in Mexico in March 2009, novel H1N1 influenza reached pandemic status on June 11, 2009 , with more than 17,700 deaths reported worldwide as of March 2010 [3] .
Numerous epidemiologic studies have clinically characterized novel H1N1 and identified risk factors for severe disease in the general population [4] [5] [6] [7] [8] .
Patients who are immunocompromised seem to be at greater risk for severe influenza-associated complications, prolonged viral shedding, and emergence of antiviral drug resistance [9, 10] . An early report from hospitalized patients with novel H1N1 in California [4] , and a larger series from Canada that included 168 critically ill patients [11] , described the presence of an underlying immunosuppressive disorder in 20% of cases.
Hematopoietic stem cell transplantation (HSCT) recipients often remain profoundly immunosuppressed after transplantation, depending on such comorbidities as graft-versus-host disease (GVHD) and the need for ongoing immunosuppression [12] , and are at high risk for severe infection. Community-acquired respiratory viruses, such as respiratory syncytial virus (RSV), parainfluenza viruses, and influenza viruses, are relatively common causes of both upper respiratory tract infection (URTI) and lower respiratory tract infection (LRTI) in this patient population and are associated with significant morbidity and mortality [13, 14] .
Historically, the H1N1 pandemic is the first influenza pandemic to hit since the introduction of HSCT into clinical practice. Case reports of H1N1 infection after HSCT have been published [9, 15, 16] , as has a single-center series from a major cancer center that included 21 HSCT recipients [17] . In the present work, we present and analyze the clinical characteristics and outcomes of 27 recipients of HSCT (22 allogeneic HSCT and 5 autologous HSCT) with proven or probable novel H1N1 influenza at two academic medical centers in the United States.
METHODS

Identification of Patient Population
Data reports from the Infection Control Departments at the University of California San Diego (UCSD), Oregon Health and Science University (OHSU), and OHSU's Center for Hematologic Malignancies were used for case identification. In 2009, a total of 139 HSCTs (79 autologous and 60 allogeneic) were performed at UCSD, and 122 (66 allogeneic and 56 autologous) were performed at OHSU. Each patient included was at least 18 years old, had been diagnosed with influenza, and had undergone allogeneic or autologous HSCT.
Novel H1N1 Influenza Identification
Four standard techniques were used to identify influenza: influenza-specific reverse-transcriptase polymerase chain reaction (RT-PCR; ViraCor Laboratories, Lee's Summit, MO; RT-PCR provided by the Centers for Disease Control and Prevention [CDC] and performed by state Health Departments) or respiratory virus PCR multiplex panel (Luminex, Austin, TX), direct fluorescent antibody (DFA) testing (Diagnostic Hybrids, Diagnostics Hybrids, Athens, OH), rapid influenza testing (BinaxNOW, Binax NOW, Inverness Medical Professional Diagnostics, Princeton, NJ), and viral culture. Samples were collected from nasal wash, nasopharyngeal swab, and/or bronchoalveolar lavage.
Case Definitions
Proven cases were defined as having confirmed novel H1N1 influenza by PCR. Probable cases were defined as patients who had a positive test for influenza A in the context of widespread community H1N1 activity without PCR confirmation. The case definition of classic influenza-like illness (ILI) included fever $100.4 F and at least two of the following symptoms: cough, myalgia, sore throat, and headache. Patients who did not meet the criteria for classic ILI were considered to have an atypical presentation. URTI was defined as a proven or probable case of influenza with a clear chest radiograph and/or normal findings on chest auscultation. LRTI was defined as hypoxia and/or abnormal findings on chest auscultation with new radiographic findings. Hospital-acquired infection was defined as symptom onset $7 days after admission. Influenza-related mortality was defined as death resulting from a clinically compatible illness confirmed to be influenza by diagnostic testing, with no period of complete recovery between onset of illness and death.
Data Collection
Medical records of patients meeting the foregoing inclusion criteria were retrospectively reviewed for underlying illnesses, immunosuppressive medication regimens, presenting symptoms, physical examination findings, results of pertinent radiographic studies and laboratory tests, coinfections, treatments, and outcomes. Institutional Review Board approval was obtained at both centers.
Statistical Analysis
Categorical variables were described as count and relative frequency (%). Continuous variables were summarized as averages, medians, and ranges. Categorical variables were compared using Fisher's exact test, and continuous variables were compared using the Student t test. All P values were two-tailed, and statistical significance was set at P \ .05.
RESULTS
Baseline Characteristics
Twenty-seven HSCT recipients with proven or probable H1N1 influenza A were identified at the subject institutions between May 4, 2009, and December 18, 2009 . Twenty patients were male (74%), and the average patient age was 46 years (range, 20-67 years) ( Table 1) . Twenty-two patients had received an allogeneic HSCT (11 matched unrelated and 11 matched related), and 5 had received an autologous HSCT. Seven patients were receiving chemotherapy for relapsed disease at the time of influenza diagnosis. The median time posttransplantation was 379 days (range, 5-2895 days). Six patients (22%) were diagnosed before day 100 posttransplantation, and 14 patients (52%) were diagnosed at 1 year or longer posttransplantation. Eighteen patients had stable trilineage engraftment, 4 were transfusion-dependent, and 5 were early posttransplantation and had not yet engrafted. Fourteen patients were lymphopenic (absolute lymphocyte count \500 cells/mm 3 ) at the time of influenza diagnosis. Seventeen patients (63%) had GVHD (1 acute and 16 chronic), and 12 patients (44%) were receiving systemic prednisone equivalent at a dose of $20 mg/day. Three patients had received the inactivated H1N1 influenza vaccine before diagnosis, at 0, 14, and 17 days before the onset of symptoms and 205, 468, and 2968 days posttransplantation, respectively.
Clinical Presentation
Five patients were managed as outpatients, and 22 were managed as inpatients. Five of the inpatient cases were hospital-acquired (1 developed symptoms on day 9 of admission; the other 4 developed symptoms .14 days after admission), and 17 cases presented from the community with a primary respiratory illness and were ultimately diagnosed with influenza. Of the 17 patients admitted for ILI, reasons for admission included dyspnea and hypoxia in 10, fever in 1, hypotension in 1, and observation in 5.
The most common clinical symptoms at presentation were cough, fever (temperature $100.4 F), and dyspnea ( Table 2 ). Fever ranged from 100.4 F to 103 F. Gastrointestinal symptoms (nausea, diarrhea) were present in 7 patients (26%), 4 of whom had a current or previous history of GVHD of the gastrointestinal system. Central nervous system symptoms were reported in 2 patients, one with dizziness and the other with altered mental status. Only 16 patients (59%) had classic symptoms as defined by the case criteria for ILI. Fourteen patients were diagnosed with LRTI (13/22 [59%] of allogeneic HSCT recipients and 1/5 [20%] of autologous HSCT recipients; P 5 .16); the remaining 13 had URTI. The incidence of LRTI was 67% in those at \100 days posttransplantation and 48% in those at $100 days posttransplantation (P 5 .60).
Seventy-seven percent of the patients with URTI (10/13) met the case criteria for classic ILI, compared with only 43% (6/14) of those with LRTI.
Radiographic Studies
Chest imaging was performed in 25 patients. Eleven patients had a normal chest radiograph at time of diagnosis, and 14 had evidence of LRTI. Eleven patients had diffuse bilateral infiltrates, and 3 exhibited lobar consolidation.
Virologic Diagnosis
Influenza A was documented in all 27 patients studied. PCR testing to confirm novel H1N1 was performed in 17 cases (63%), all of which were positive (Table 3) . Probable H1N1 was diagnosed by a combination of rapid test, DFA, and/or culture in the remaining patients. DFA was performed at only one of the institutions. Of the 8 DFAs performed, 7 were positive (4 from bronchoalveolar lavage [BAL] and 3 from nasopharyngeal swabs); one of these 7 was confirmed to be novel H1N1 by PCR. Patients with URTI were diagnosed significantly earlier than those with LRTI (mean, 2.69 days vs 5.62 days after symptom onset; P 5 .02; 95% CI, 0.3-5.5). The 3 patients who received vaccination before disease onset had PCR-documented novel H1N1 influenza.
Treatment
Twenty-five patients (93%) received antiviral treatment during the course of their illness. Nineteen received oseltamivir monotherapy, 3 received a combination of osteltamivir and rimantidine, and 3 received sequential therapy, 2 of whom received peramavir ( Table 4 ). The initial dose of oseltamivir was 75 mg twice daily in all patients except 1, who received an initial dose of 150 mg twice daily. The starting dose of 75 mg was increased to 150 mg twice daily in 5 patients. Treatment was initiated at a median of 3 days (range, 1-14 days) after onset of symptoms. Empiric antiviral treatment was initiated at the time of clinical diagnosis in 13 patients. Therapy was not initiated until virologic diagnosis in 12 patients, including all 5 hospitalacquired cases. Two patients did not receive treatment for influenza; one of these patients was diagnosed postmortem, and the other did not fill the prescription. Twenty-four patients receiving antiviral therapy had a clearly defined time of symptom onset. Patients with URTI were started on antiviral therapy earlier than those with LRTI (mean, 3.0 days vs 6.58 days after onset of symptoms; P 5 .03; 95% CI, 0.29-6.8).
Half of the patients with LRTI (7/14) required mechanical ventilation, 35% (5/14) required noninvasive supplemental oxygen, and 14% (2/14) did not need supplemental oxygen. Twenty patients (74%) received empiric, broad-spectrum antibiotic therapy. Baseline steroid dose was increased after influenza diagnosis in 12 patients (44%), for indications that included adult respiratory distress syndrome (ARDS) and cryptogenic organizing pneumonia.
Outcomes
All-cause mortality was 33% (9/27) at a median of 83 days (range, 5-196 days) after diagnosis of influenza. Overall influenza-related mortality was 22% (6/27) at a median of 8 days (range, 5-12 days). All patients with URTI (13/27) survived without long-term complications attributable to influenza. No patients in this series progressed from URTI to LRTI after diagnosis of H1N1 influenza. The incidence of influenza pneumonia (LRTI) was 52% (14/27), with a mortality of 43% (6/14). Rapidly progressive respiratory failure with ARDS developed in 7 patients (26%), all of whom required mechanical ventilation; only one of these patients survived to be extubated and discharged, but this patient died at day 64 of liver failure and sepsis. All deaths occurred in the LRTI group, and only one patient survived intubation, for a short period.
Three patients died .30 days after influenza was diagnosed. In addition to the patient described earlier, one patient suffered a fatal pulmonary embolus after undergoing colectomy for severe Clostridium difficile colitis, and the other had bronchiolitis obliterans. These patients died at 63 and 120 days after diagnosis, respectively. Other possible influenza-related complications included one case of myopericarditis and one death resulting from massive myocardial infarction in the context of known severe coronary artery disease.
Diagnostic BAL (for bacterial and viral studies) was performed in 8 of the 14 patients with LRTI. Nonquantitative bacterial cultures were positive in 2 of these patients, although in both cases the treating physician considered this to represent colonization rather than actual infection. One of these patients (patient 5) demonstrated pleural effusion (known to be malignant effusion) on chest radiograph and growth of oral flora and Escherichia coli in BAL fluid. The second patient (patient 10) had hospital-acquired H1N1 and a remote history of treatment for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. MRSA grew from BAL cultures, and the patient received vancomycin leading up to and after bronchoscopy, although the treating physician suspected that this represented colonization. There were no other suspected or documented bacterial superinfections. One patient (patient 10) was found to be coinfected with adenovirus at the time of influenza diagnosis.
Another patient (patient 22) had documented oseltamivir resistance with mutation H275Y (CDC and ViraCor Laboratories). This patient received an initial 5-day course of oseltamivir, then a 15-day hiatus in antiviral treatment, followed by a 3-day course of oseltamivir, and finally a 6-day course of intravenous peramivir. Active viral shedding was documented for 28 days. This was the only patient tested for antiviral resistance based on clinical suspicion.
A steroid dose of $20 mg/day of prednisone equivalent at the time of influenza diagnosis was significantly associated with the development of LRTI (71% vs 15%; P 5 .006) and with 30-day mortality (50% vs 0%; P 5 .003). A trend toward an association of lymphopenia with LRTI was seen (71% vs 31%; P 5 .057) ( Table 5 ).
DISCUSSION
Previous reports have provided insight into the clinical features and sequelae of seasonal influenza in HSCT recipients [18, 19] . To date, there have been only limited reports of H1N1 influenza in the same population, however. Here, we report a series of 27 HSCT patients with H1N1 influenza at two institutions.
The most common symptoms were fever and cough, consistent with findings from a previous series of novel H1N1 influenza in HSCT recipients and indistinct from the clinical picture of other respiratory viral infections [20] . The atypical presentation in patients with LRTI was quite notable in our series. The absence of classic presenting symptoms has been well characterized with other respiratory viral infections in HSCT patients, in whom pneumonia may develop with mild or absent URTI-type symptoms [14, 21] . The impaired systemic inflammatory response and immune dysregulation observed in immunosuppressed HSCT recipients might contribute to these atypical presentations.
The most common serious complication in our series was influenza pneumonia, occurring in more than half of the patients. This is higher than the incidence of LRTI reported with seasonal influenza in HSCT recipients (5%-44%) [13, 18, 19, 22, 23] and with that of novel H1N1 influenza in hospitalized patients (40%-44%) [8, 24] . Half of the patients with LRTI progressed to ARDS relatively rapidly after the initial clinical presentation. This incidence is also higher than the incidence of ARDS in reports of novel H1N1 influenza in other populations, which has ranged from 0 to 24% [8, 24, 25] . The lack of clearly documented bacterial superinfections may well result from the early empiric use of broad-spectrum antibiotics in this patient population.
Chronic corticosteroids and lymphopenia have been identified as risk factors for the progression from URTI to LRTI in HSCT recipients with respiratory virus infection [14, 26] . In our series, the use of $20 mg/day of prednisone equivalent at time of diagnosis was associated with LRTI and mortality. These findings are limited by the reliance on univariate analysis, which does not allow for independent assessment of steroid use and LRTI as risk factors for mortality. In addition, there was a trend toward more lymphopenia in the LRTI group and in those with \30-day mortality, but these associations failed to reach statistical significance. Given the small number of patients in this series, these findings will need to be confirmed in larger future studies.
Two patients with confirmed novel H1N1 influenza received the inactivated vaccine roughly 2 weeks before symptom onset and more than 1 year after HSCT. In healthy U.S. adults and elderly persons, a single dose of vaccine for novel H1N1 was found to be highly immunogenic when evaluated at 3 weeks postvaccination [27, 28] . However, the immunologic response to influenza vaccination is suboptimal in HSCT recipients, particularly those who recently underwent transplantation and those on high-dose immunosuppressive therapy [29, 30] .
Early initiation of antiviral therapy in patients with H1N1 influenza infection may attenuate the severity of disease [8, 31, 32] . In our series, those with LRTI were started on antiviral therapy significantly later after symptom onset compared with the URTI group. This discrepancy may be related to a failure to recognize atypical presentations of influenza illness, contributing to delayed diagnosis in HSCT recipients with LRTIs. We also recognize the increasing institutional awareness of H1N1 influenza infections over time. Thus, patients might have been more aggressively screened and treated with antiviral therapy later in the course of the pandemic, thereby decreasing the delays in starting therapy and possibly avoiding the development of LRTI.
Apart from LRTI, other complications noted in this series included a case of myopericarditis and an autopsy-confirmed case of bronchiolitis obliterans. Respiratory virus infections in allogeneic HSCT and lung transplant recipients have been demonstrated to trigger alloimmune lung syndromes, such as bronchiolitis obliterans and idiopathic pneumonia syndrome, and are associated with increased mortality [33, 34] .
The 30-day mortality in our series (22% overall, and 43% in the subset with LRTI) was higher than that reported with seasonal influenza A in HSCT recipients, (0-15% and 0-28%, respectively) [13, 14, 18, 19, 22, 23] , and was significantly higher than that reported with novel H1N1 in hospitalized patients at large (0-7%) [8, 24, 35] . Redelman-Sidi et al. [17] reported no influenza-related mortality in a group of 21 HSCT recipients with H1N1 infection at their center. The striking disparity in mortality between that series and ours is likely related to a number of factors. Our series included more patients with LRTI (52% vs 40%), GVHD (63% vs 19%), and early (\5 months) posttransplantation status (22% vs 0%). The higher rates of LRTI and death in our series compared with both seasonal and novel H1N1 reports in HSCT might be a result of selection bias, if H1N1 was more frequently considered and tested for in the sicker patients. Therefore, the incidence of severe influenza is likely overestimated in this study.
Nosocomial outbreaks of seasonal influenza have been well described [36] [37] [38] . Nineteen percent of our patients had hospital-acquired influenza. Antiviral treatment in this group was uniformly initiated at the time of microbiologic diagnosis rather than at the onset of clinical symptoms. At one of the centers, no further nosocomial cases were documented after implementation of unit-wide contact/droplet isolation and visitor restriction policies, along with a low threshold for influenza testing. Vaccination of health care workers is another effective way to reduce nosocomial transmission of influenza. Although the estimated rate of seasonal influenza vaccination rates in health care workers is only 40% [39] , mandatory vaccination has been found to increase vaccination rates [40] . The present study has several limitations, including its retrospective design and small sample size. In addition, our series likely does not include all HSCT patients with influenza, given that patients were captured on the basis of clinical symptoms rather than on universal screening. Thus, patients with very mild signs and/or symptoms of infection might not have been identified. Only 63% of the cases were confirmed as novel H1N1 influenza by PCR. Probable cases were included because H1N1 was overwhelmingly the most prevalent influenza virus in the community during the study period [41] .
In conclusion, we have reported a series of 27 HSCT recipients with novel H1N1 influenza with a high incidence of atypical presentation and severe disease. Patients with LRTI frequently required mechanical ventilation and had a high mortality rate. Our centers' experiences underscore the importance of considering influenza infection in HSCT recipients despite an often atypical presentation. Further studies are needed to confirm these findings and delineate other risk factors, clinical characteristics, treatment, and mortality of novel H1N1 influenza in this patient population.
